A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder

Journal of Clinical Psychiatry

Volumn 61, Issue 9, 2000, Pages 638-642

  Guille, C ^a   Sachs, G S ^a   Ghaemi, S N ^a  

^a CAMBRIDGE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; LITHIUM; OLANZAPINE; PROLACTIN; RISPERIDONE; VALPROATE SEMISODIUM;

AKATHISIA; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DATA BASE; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WEIGHT GAIN;

EID: 0033798320     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v61n0907     Document Type: Article

References (35)

1. Antipsychotic agents and bipolar disorder
2. Use of atypical antipsychotic agents in bipolar disorder and schizoaffective disorder: Review of the empirical literature
3. Risperidone in the treatment of affective illness and obsessive-compulsive disorder
4. Risperidone in the treatment of mania
5. Acute treatment of bipolar disorder with adjunctive risperidone in outpatients
6. Long-term risperidone treatment in bipolar disorder: 6 Month follow-up
7. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder
8. Risperidone therapy in treatment refractory acute bipolar and schizoaffective mania
9. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders
10. Efficacy and safety of risperidone in bipolar disorder
11. Clinical predictors of acute response with olanzapine in psychotic mood disorders
12. Olanzapine in treatment-resistant bipolar disorder
13. Olanzapine treatment of mood disorders
14. Long-term olanzapine treatment of mania
15. Risperidone compared with both lithium and haloperidol in mania: A double-blind randomized controlled trial
16. Olanzapine versus placebo in the treatment of acute mania
17. Olanzapine: A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses
18. Risperidone: Efficacy and safety
19. The prevalence and severity of acute extrapyramidal side effects in patients treated with clozapine, risperidone, or conventional antipsychotics
20. Comparison of extrapyramidal syndrome with haloperidol and risperidone
21. Risperidone in the treatment of schizophrenia
22. Risperidone in the treatment of patients with chronic schizophrenia: A multi-center, double-blind, parallel group study versus haloperidol
23. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications
24. Extrapyramidal symptoms in patients treated with risperidone
25. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreni-form disorders: Results of an international collaboration
26. Medical hazards of obesity
27. Side effect profiles of new antipsychotic agents
28. Novel antipsychotics: Comparisons of weight gain liabilities
29. Neuropharmacology of obesity: My receptors made me eat it
30. The search for human obesity genes
31. Weight gain associated with neuroleptic medication: A review
32. Movement disorders associated with serotonin selective reuptake inhibitors
33. A pilot study on risperidone metabolism: The role of cytochromes P450 2D6 and 3A
34. Risperidone treatment for juvenile bipolar disorder: A retrospective chart review